UBS Group’s PTC Therapeutics PTCT Stock Holding History

UBS Group’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-296,100	Closed	-$9.59M	–	8049
2015 Q4	$9.59M	Buy	+296,100	New	+$8.71M	0.01%	1435

Other funds holding PTCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

UBS Group's PTCT Position: Q1 2026 in Review

UBS Group increased its PTC Therapeutics (PTCT) stake by 41% in Q1 2026, buying an estimated $28.3M and bringing the position to 1,364,768 shares worth $93M. The position accounts for 0.01% of the portfolio, ranked #1108.

UBS Group first reported a position in PTCT in Q4 2014 and has held it in 46 quarters since. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

UBS Group held 1,364,768 shares of PTC Therapeutics worth $93M as of Q1 2026.
UBS Group bought 400,110 PTC Therapeutics shares in Q1 2026, an estimated $28.3M.
PTC Therapeutics made up 0.01% of UBS Group's portfolio in Q1 2026, its #1108 holding.
UBS Group first reported a position in PTC Therapeutics in Q4 2014 and has held it in 46 quarters since.
350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.